期刊文献+

非布司他治疗前后的原发性痛风患者的超声影像学比较 被引量:5

下载PDF
导出
摘要 目的通过超声影像学对非布司他治疗痛风性关节炎的效果进行验证。方法对20例临床确诊的原发性痛风患者应用非布司他治疗前后的受累关节的超声表现进行比较。结果排除2例脱落患者,18例受试患者治疗24周后,关节软骨双轨征、关节积液、滑膜增厚、关节液内暴雪样回声、肌腱周围强回声均明显减少,血流信号变弱,与治疗前比较差异均有统计学意义(P<0.05)。结论非布司他可有效的改善痛风患者病情,高频超声影像学检查可以作为判断非布司他治疗效果的一项重要依据。
出处 《中国现代药物应用》 2016年第10期144-145,共2页 Chinese Journal of Modern Drug Application
  • 相关文献

参考文献3

  • 1蒋兰兰,金星,沈赟,马建华,吴锦丹.非布司他治疗痛风伴高尿酸血症患者的有效性及安全性[J].实用医学杂志,2014,30(17):2827-2830. 被引量:97
  • 2Alexander KS, Kay-Geert AH, Elke K, et al. A novel uhrasonographic synovitis scoring system suitable for analyzing finger joint inflammation in rheumatoid arthritis. Arthritis Rheum, 2005, 52(3): 733-743.
  • 3Thiele RG, Schlesinger N. Ultrasonography shows disappearance of monosodium urate crystal deposition on hyaline cartilage after sustained normouricemia is achieved. Rheumatol Int, 2010, 30(4): 495-503.

二级参考文献10

  • 1Terkeltauh R, Bushinsky DA, Becker MA. Recent developments in our understanding of the renal basis of hyperuricemia and the development of novel antihyperuricemic therapeutics [J]. Arthritis Res Ther, 2006, 8( Suppl 1) : S4.
  • 2Chao 1, Terkeltaub R. A critical reappraisal of allopurinol dosing, safety, and efficacy for hyperuricemia in gout [J]. CUff Rheumatol Rep, 2009,11 (2): 135-140.
  • 3Tayar JH, Lopez-Olivo MA, Suarez-Almazor ME. Febuxostat for treating chronic gout [J]. Cochrane Database Syst Rev, 2012, 14 (1):11.
  • 4Schumacher HR, Becker MA, Wortmann RL, et al. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase ill , randomized, double-blind, parallel-group trial [J]. Arthritis Rheum, 2008,59(11):1540-1548.
  • 5Schumacher HR, Becker MA, Lioyd E, et al. Febuxostat in the treatment of gout: 5-yr findings of the FOCUS efficacy and safety study [J]. Rheumatology(Oxford), 2009,48(2): 188-194.
  • 6El-Zawawy H, Mandell BF. Managing gout: how is it different in patients with chronic kidney disease? [J]. Cleve Clin J Med, 2010,77(12):919-928.
  • 7Ernst ME, Fravel MA. Febuxostat , a selective xanthine-oxidase/ xanthine-dehydrogenase inhibitor for the management of hyperuricemia in adults with gout [J]. Clin Ther, 2009, 31 ( 11 ) : 2503-2518.
  • 8Ye P, Yang SM, Zhang WL, et al. Efficacy and tolerability of febuxostat in hyperuricemic patients with or without gout: a systematic review and meta-analysis [J]. Clin Ther, 2013 , 35 (2): 180-189.
  • 9Becker MA, Schumacher HR Jr , Espinoza L, et al. A phase 3 randomized, controlled, multicenter, double-blind trial (RCT) comparing efficacy and safety of daily febuxostat (FEB) and allopurinol (ALLO) in subjects with gout [J]. Arthritis Rheum, 2008,58(suppI9) :L11.
  • 10Zhang W, Doherty M, Pascual E, et al. EULAR evidence based recommendations for gout. Part II: management. Report of a task force of the Standing Committee for international Clinical Studies Including Therapeutics (ESCISIT) [J]. Ann Rheum Dis, 2006, 65( 10): 1312-1324.

共引文献96

同被引文献32

引证文献5

二级引证文献34

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部